rp3
Biologicalexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 29, 2020 (NCT04735978)
Timeline
Indications
Mechanism of action
- Oncolytic virusOTHER
Oncolytic virus other
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05733598 | Phase 2 | Apr 1, 2024 | Replimune Inc., Roche |
| NCT05743270 | Phase 2 | Jan 30, 2024 | Bristol-Myers Squibb, Replimune Inc. |
| NCT05733611 | Phase 2 | Jun 29, 2023 | Replimune Inc., Roche |
| NCT04735978 | Phase 1 | Dec 29, 2020 | Replimune Inc. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Replimune Inc. | For profit | 4 | 4 | 2 | 2020 |
| Roche | For profit | 2 | 0 | 1 | 2023 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1